Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice

Taking immunogenicity assessment of therapeutic proteins to the next level

(2011) I.C. Büttel et al.   BIOLOGICALS

Requirements for immune recognition and processing of factor VIII by antigen-presenting cells

(2011) Simon D. van Haren et al.   BLOOD REVIEWS

Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization

(2011) Satwinder Kaur Singh et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Contributions of Gene Marking to Cell and Gene Therapies

(2011) Cecilia N. Barese et al.   HUMAN GENE THERAPY

C1 domain residues Lys 2092 and Phe 2093 are of major importance for the endocytic uptake of coagulation factor VIII

(2011) Henriët Meems et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain

(2011) Eszter Herczenik et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Induction of tolerance to factor VIII by transient co-administration with rapamycin

(2011) B. MOGHIMI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Suppression of the Immune Response to FVIII in Hemophilia A Mice by Transgene Modified Tolerogenic Dendritic Cells

(2011) Rui-Jun Su et al.   MOLECULAR THERAPY

Storage of Factor VIII Variants with Impaired von Willebrand Factor Binding in Weibel-Palade Bodies in Endothelial Cells

(2011) Maartje van den Biggelaar et al.   PLoS One

A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function

(2010) J. Lu et al.   BLOOD

TLR signalling regulated antigen presentation in dendritic cells

(2010) Colin Watts et al.   CURRENT OPINION IN IMMUNOLOGY

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆

(2009) Satoshi Nagata et al.   ADVANCED DRUG DELIVERY REVIEWS

Can we prevent immunogenicity of human protein drugs?

(2009) D W Scott et al.   ANNALS OF THE RHEUMATIC DISEASES

Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity

(2009) H. Meems et al.   BLOOD

A role for thrombin in the initiation of the immune response to therapeutic factor VIII

(2009) J. Skupsky et al.   BLOOD

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

(2009) M. M. van Luijn et al.   HAEMATOLOGICA

Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A

(2009) A. PAVLOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Strategies for Analysis of the Glycosylation of Proteins: Current Status and Future Perspectives

(2009) Susan A. Brooks   MOLECULAR BIOTECHNOLOGY

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response

(2008) B. Waters et al.   BLOOD

IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A

(2008) Pauline M. W. van Helden et al.   BRITISH JOURNAL OF HAEMATOLOGY

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation

(2008) S. Dasgupta et al.   HAEMATOLOGICA

The disappearing act of factor VIII

(2008) P. J. LENTING et al.   HAEMOPHILIA